Procalcitonin is Not an Independent Predictor of 30-day Mortality, Albeit Predicts Pneumonia Severity in Patients with Pneumonia Acquired Outside the Hospital

Overview

Journal BMC Geriatr

Publisher Biomed Central

Specialty Geriatrics

Date 2019 Jan 9

PMID 30616612

Citations 8

Authors

Takanori Akagi

Nobuhiko Nagata

Hiroyuki Miyazaki

Taishi Harada

Satoshi Takeda

Yuji Yoshida

Kenji Wada

Masaki Fujita

Kentaro Watanabe

Affiliations

Soon will be listed here.

Abstract

Background: Procalcitonin (PCT) is a useful marker for pneumonia. However, its clinical usefulness in elderly patients has not been studied extensively. This study aimed to assess the relationship between PCT and prognosis and pneumonia severity in elderly patients with pneumonia acquired outside the hospital.

Methods: Data considered relevant to pneumonia severity and prognosis were retrospectively obtained from clinical charts of all patients with pneumonia who were admitted to our hospital from 2010 to 2017. The primary outcome was 30-day mortality in elderly patients (aged ≥75 years), and the relationship between PCT levels and pneumonia severity, as determined by the pneumonia severity index (PSI) was also examined.

Results: Data were collected from 667 patients, of which 436 were elderly patients. Multivariate and receiver operating characteristic curve analysis revealed that albumin, body mass index, and PSI class rather than PCT are important factors related to 30-day mortality in elderly patients. PCT was also not an independent prognostic factor in younger patients. PCT levels significantly differed by pneumonia severity (mild, moderate, and severe) in both younger (p < 0.001) and elderly (p < 0.0001) patients, with levels increasing as severity increased. In contrast, C-reactive protein (CRP) levels and white blood cell counts did not significantly differ by pneumonia severity in younger and elderly patients. A subgroup analysis focused on Streptococcus pneumoniae pneumonia revealed that PCT levels differed by severity in elderly patients (p = 0.03), with levels increasing as severity increased.

Conclusion: PCT was not an independent predictor of 30-day mortality in both of elderly and younger patients. PCT levels, but not CRP levels, significantly increased with increasing pneumonia severity in younger and elderly patients, although the degree of increase tended to be lower in elderly patients compared to younger patients for the same severity. PCT levels also significantly increased with increasing pneumonia severity in elderly patients with Streptococcus pneumoniae pneumonia.

Citing Articles

Evaluating the Effect of Body Mass Index on Procalcitonin Level in Patients with Pneumonia: A Retrospective Cross-Sectional Study.

Khrais M, Henson J, Smith J, Meena N Adv Respir Med. 2025; 93(1).

PMID: 39996618 PMC: 11851394. DOI: 10.3390/arm93010001.

Procalcitonin, C-reactive protein, and white blood cell count levels in end-stage cancer patients: A retrospective study on inflammatory markers and their prognostic value.

Zhou Q, Lu X, Qian L, Yu C, Xie J, Kong D Medicine (Baltimore). 2024; 103(49):e40792.

PMID: 39654236 PMC: 11631015. DOI: 10.1097/MD.0000000000040792.

Prognosis prediction of procalcitonin within 24 h for acute diquat poisoning.

He C, Liang L, Zhang Y, Wang T, Wang R BMC Emerg Med. 2024; 24(1):61.

PMID: 38616281 PMC: 11017620. DOI: 10.1186/s12873-024-00975-2.

Evaluation of the factors affecting long-term mortality in geriatric patients followed up in intensive care unit due to hospital-acquired pneumonia.

Aydemir S, Hosgun D Medicine (Baltimore). 2022; 101(38):e30645.

PMID: 36197164 PMC: 9509032. DOI: 10.1097/MD.0000000000030645.

Identification of RAGE and OSM as New Prognosis Biomarkers of Severe Pneumonia.

Lei J, Wang L, Li Q, Gao L, Zhang J, Tan Y Can Respir J. 2022; 2022:3854191.

PMID: 35035643 PMC: 8759921. DOI: 10.1155/2022/3854191.

References

Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M . Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2017; 18(1):95-107. DOI: 10.1016/S1473-3099(17)30592-3. View

Lacoma A, Rodriguez N, Prat C, Ruiz-Manzano J, Andreo F, Ramirez A . Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2011; 31(5):825-33. DOI: 10.1007/s10096-011-1381-0. View

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

Huang D, Weissfeld L, Kellum J, Yealy D, Kong L, Martino M . Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008; 52(1):48-58.e2. PMC: 2775454. DOI: 10.1016/j.annemergmed.2008.01.003. View

Goronzy J, Weyand C . Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013; 14(5):428-36. PMC: 4183346. DOI: 10.1038/ni.2588. View

Lee J, Kim J, Kim K, Jo Y, Rhee J, Kim T . Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J Crit Care. 2010; 26(3):287-94. DOI: 10.1016/j.jcrc.2010.10.007. View

Kim M, Lim J, Oh S . Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia. Scand J Clin Lab Invest. 2017; 77(7):486-492. DOI: 10.1080/00365513.2017.1344298. View

Johansson N, Kalin M, Backman-Johansson C, Larsson A, Nilsson K, Hedlund J . Procalcitonin levels in community-acquired pneumonia - correlation with aetiology and severity. Scand J Infect Dis. 2014; 46(11):787-91. DOI: 10.3109/00365548.2014.945955. View

Kim J, Seo J, Mok J, Kim M, Cho W, Lee K . Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia. Tuberc Respir Dis (Seoul). 2013; 74(5):207-14. PMC: 3672412. DOI: 10.4046/trd.2013.74.5.207. View

10.

Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, Bingisser R, Miedinger D . Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med. 2008; 264(2):166-76. DOI: 10.1111/j.1365-2796.2008.01934.x. View

11.

Ito A, Ishida T, Tokumasu H, Washio Y, Yamazaki A, Ito Y . Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort. BMC Pulm Med. 2017; 17(1):78. PMC: 5414343. DOI: 10.1186/s12890-017-0424-4. View

12.

Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B . Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2010; 37(2):384-92. DOI: 10.1183/09031936.00035610. View

13.

Franceschi C, Campisi J . Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1:S4-9. DOI: 10.1093/gerona/glu057. View

14.

Stucker F, Herrmann F, Graf J, Michel J, Krause K, Gavazzi G . Procalcitonin and infection in elderly patients. J Am Geriatr Soc. 2005; 53(8):1392-5. DOI: 10.1111/j.1532-5415.2005.53421.x. View

15.

Tanriverdi H, Tor M, Kart L, Altin R, Atalay F, SumbSumbuloglu V . Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia. Ann Thorac Med. 2015; 10(2):137-42. PMC: 4375743. DOI: 10.4103/1817-1737.151442. View

16.

Zhang H, Wang X, Zhang Q, Xia Y, Liu D . Comparison of procalcitonin and high-sensitivity C-reactive protein for the diagnosis of sepsis and septic shock in the oldest old patients. BMC Geriatr. 2017; 17(1):173. PMC: 5540304. DOI: 10.1186/s12877-017-0566-5. View

17.

Shi Y, Xu Y, Rui X, Zhang H, Wang Y, Du W . Procalcitonin kinetics and nosocomial pneumonia in older patients. Respir Care. 2013; 59(8):1258-66. DOI: 10.4187/respcare.02364. View

18.

Masia M, Gutierrez F, Shum C, Padilla S, Navarro J, Flores E . Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest. 2005; 128(4):2223-9. DOI: 10.1378/chest.128.4.2223. View

19.

Gomez-Cerquera J, Daroca-Perez R, Baeza-Trinidad R, Casanas-Martinez M, Mosquera-Lozano J, Ramalle-Gomara E . Validity of procalcitonin for the diagnosis of bacterial infection in elderly patients. Enferm Infecc Microbiol Clin. 2014; 33(8):521-4. DOI: 10.1016/j.eimc.2014.10.019. View

20.

Mandell L, Wunderink R, Anzueto A, Bartlett J, Campbell G, Dean N . Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72. PMC: 7107997. DOI: 10.1086/511159. View